This is a working overview of impurity profile, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-07-15 and is reviewed periodically as new material appears.
Stability testing examines how peptide purity changes over time under defined conditions. Accelerated studies use elevated temperatures and humidity to predict degradation pathways, while long-term studies store samples at recommended temperatures. Common degradation reactions include oxidation of methionine, deamidation of asparagine, and hydrolysis of peptide bonds. The results inform expiration dates and storage recommendations for research materials. Lyophilized peptides are generally more stable than solutions, but both forms can degrade if exposed to moisture, oxygen, or repeated freeze-thaw cycles.
Impurity profiling identifies and quantifies substances that coexist with the target peptide. These include deletion sequences, truncated peptides, oxidized variants, and residual protecting groups from synthesis. Reversed-phase chromatography can separate many of these impurities, but co-elution remains a challenge for closely related species. Mass spectrometry helps assign identities to impurity peaks, and impurity limits are often set as area percentages relative to the main peak. Regulatory guidelines for research-grade peptides are less strict than those for therapeutic products, so specifications vary by supplier.
Quality control for peptides involves setting specifications for identity, purity, and counterion content. Batches are tested against these specifications before release. Purity specifications often require a minimum area percentage by high-performance liquid chromatography, such as 95% or 98%, depending on the intended application. Additional tests may include water content, acetate or trifluoroacetate content, and residual solvents. These parameters affect the net peptide content and the accuracy of subsequent laboratory experiments.
Reverse-phase high-performance liquid chromatography is the most common primary method for peptide purity testing. The peptide mixture passes through a hydrophobic stationary phase, and components elute according to differences in hydrophobicity. A mobile phase of water and acetonitrile, often with trifluoroacetic acid as an ion-pairing agent, improves peak shape and retention. Ultraviolet detection at 214 nm records the peptide backbone absorbance, and the main peak area is divided by the total peak area to give an area-percent purity value.
Other chromatographic modes provide complementary information that reverse-phase separation may not capture. Ion-exchange chromatography separates peptides by net charge and can resolve deamidated, oxidized, or truncated variants that co-elute under hydrophobic conditions. Size-exclusion chromatography detects aggregates and higher-order oligomers, which are often invisible in reverse-phase assays. Chiral chromatography can quantify D-amino acid epimers when stereochemical purity matters. Because each mode uses a different separation principle, a single purity number from one method cannot describe all possible impurities.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature (lyophilized) | -20 °C | Long-term storage; -80 °C for extended periods |
| Typical storage temperature (solution) | -80 °C | Avoid repeated freeze-thaw; aliquot before freezing |
| Common degradation pathway | Oxidation of methionine | Affects peptides containing methionine; accelerated by oxygen |
| Common counterion | Trifluoroacetate | From HPLC purification; acetate also common |
| Purity specification (research grade) | ≥95% by HPLC area | Higher grades may require ≥98%; method-dependent |
Chromatographic separation resolves truncated, oxidized, deamidated, and epimerized peptide variants when their retention times differ from the target. Mass spectrometry confirms molecular mass and can reveal modifications that UV detection misses. Liquid chromatography coupled to mass spectrometry combines separation with identity information, which helps distinguish a pure target from a co-eluting impurity. UV-based area percent can overestimate purity if an impurity lacks a chromophore or if the target and impurity have similar response factors. Researchers often report both chromatographic purity and mass confirmation to give a fuller picture.
Additional techniques address components that reversed-phase chromatography may not resolve. Ion-exchange chromatography separates by charge, size-exclusion chromatography detects aggregates, and capillary electrophoresis offers high separation efficiency. Water content is measured by Karl Fischer titration, residual solvents by gas chromatography, and elemental impurities by inductively coupled plasma mass spectrometry. Amino acid analysis or nitrogen determination can estimate peptide content on a mass basis. Purity is frequently reported as area percent, yet standardized comparison across laboratories remains an open question because methods and reporting practices differ.
Peptide purity testing measures how much of a sample consists of the intended peptide sequence compared with related substances, water, counterions, and residual solvents. No single analytical method captures all of these components at once. Reversed-phase high-performance liquid chromatography with ultraviolet detection is widely used because it separates peptides by hydrophobicity. The reported purity value therefore depends on the chosen method, column, mobile phase, and detection wavelength. Established practice treats purity as method-dependent rather than an absolute property of the material.
Orthogonal methods reduce the chance that a single technique misses an impurity. Capillary electrophoresis separates by charge-to-size ratio and can resolve variants that co-elute under one set of HPLC conditions. Amino acid analysis reports composition after hydrolysis and confirms the presence of expected residues. Karl Fischer titration measures water content, while ion chromatography can quantify counterions. No single number captures all aspects of sample quality, so reports often combine several measurements.
Peptide purity testing uses separation methods to estimate the proportion of a sample that corresponds to the target sequence. Reverse-phase high-performance liquid chromatography is the most common technique, separating peptides by hydrophobicity on a nonpolar column. Ultraviolet detection at 214 nm records peptide bonds and aromatic residues. The resulting chromatogram is reported as area percent, which reflects relative absorbance rather than absolute mass. This distinction matters because water, counterions, and residual solvents do not appear in the peptide peak.
Mass spectrometry provides an identity check that complements chromatographic purity. Electrospray ionization or matrix-assisted laser desorption/ionization measures the mass-to-charge ratio of intact peptides. A match to the expected molecular mass supports correct sequence length and terminal groups. Mass accuracy alone does not prove that every peak in a liquid chromatogram is the target peptide. It also does not directly quantify how much water or counterion remains in a lyophilized powder.
Purity and potency are related but distinct concepts in peptide testing. Purity describes the proportion of the main peptide relative to other detected substances, while potency refers to the biological or functional activity of a defined amount. A highly pure peptide can still have low potency if it is misfolded, aggregated, or chemically modified at a critical residue. Conversely, a less pure preparation may retain high activity if the impurities are inactive. Clear reporting separates these attributes and states the assay used for each.
Peptide purity specifications describe which tests define an acceptable lot and how results are reported. A certificate of analysis commonly lists a reverse-phase HPLC purity value, a mass spectrometry identity result, water content, counterion content, and residual solvent data. The specification may set a minimum area percent, such as 95% or 98%, depending on the intended use and grade. No universal threshold applies to all peptides, because sequence length, hydrophobicity, and manufacturing route influence achievable purity.
Sampling and sample preparation influence measured purity. Peptides are often hygroscopic, so weighing should occur quickly under controlled humidity to avoid water uptake. Complete dissolution in a suitable solvent is necessary before injection; undissolved material can block columns or distort results. Filtration removes particulates but may also remove aggregates if the filter pore size is too small. Impurities can originate from synthesis, cleavage, purification, or storage, and forced degradation under heat, light, oxidation, or pH extremes can help identify degradation pathways.
Regulatory and accreditation expectations depend on the peptide's intended use. Research reagents may be tested with in-house methods, while pharmaceutical development follows validated procedures and pharmacopeial chapters where applicable. Method validation commonly examines accuracy, precision, specificity, linearity, range, and limits of detection and quantitation. Laboratories accredited to ISO/IEC 17025 must document competence, equipment calibration, and uncertainty. Comparing purity results across laboratories remains difficult because different columns, gradients, detection wavelengths, and integration rules can change reported values; open questions include how best to standardize impurity identification and reporting for diverse peptide products.
Quality control for peptides places purity testing within a documented system that includes specifications, test methods, and acceptance criteria. A certificate of analysis typically reports appearance, chromatographic purity, mass confirmation, and storage conditions. System suitability checks, blank injections, and reference standards help ensure that an analytical run is valid. Traceability requires records of sample preparation, instrument settings, and data processing. No single purity threshold applies to all peptides or uses, so specifications are set according to the intended application and risk assessment.
Beginning in the 1950s, The Walt Disney Company began producing made-for-television films in their long-running anthology series Disneyland (later to be popularly known as The Wonderful World of Color and The Wonderful World of Disney). Many of Disney's TV movies were miniseries that aired in installments over several weeks, and a few (such as Davy Crockett and The Scarecrow of Romney Marsh) were later re-edited and released theatrically. During the 1980s, in addition to films made for their weekly TV series, Disney began making original films for their television network, The Disney Channel. After the acquisition of ABC in the 1990s, Disney began co-producing uncharacteristic films (Stephen King's Storm of the Century, Home Alone 4) as well as TV reunion movies (The Facts of Life Reunion, The Growing Pains Movie) and a few in conjunction with Hallmark Entertainment (Dinotopia, Mr. St. Nick, Snow White: The Fairest of Them All).
== Dynamic features == β-pleated sheet structures are made from extended β-strand polypeptide chains, with strands linked to their neighbours by hydrogen bonds. Due to this extended backbone conformation, β-sheets resist stretching. β-sheets in proteins may carry out low-frequency accordion-like motion as observed by the Raman spectroscopy and analyzed with the quasi-continuum model.
=== Gingival crevicular fluid as a biomarker source === For research purposes, utilisation of GCF (gingival crevicular fluid) or PISF (peri-implant sulcular fluid) have been proven to be reliable indicators to examine gingival health, though this is rarely done in clinical practice. Through saliva samples obtained from individuals, the GCF/PISF mixed within saliva have been studied for the level of cytokines and inflammatory mediators. Examples of these mediators include Interleukin (IL) 1-ß, IL-6, macrophage chemotactic protein, interferon g-induced protein 10 (IP-10) and vascular endothelial growth factor (VEGF). Results indicate that individuals with periodontal disease have a significant increase in cytokine count compared to individuals who are of good gingival health. This is explained to be due to the increased interaction between the bacterial biofilm and the cells of the periodontal tissue, leading to heightened diffusion of these mediators along with the GCF into the gingival sulcus.
Sources: en.wikipedia.org
tPA and plasmin are the key enzymes of the fibrinolytic pathway in which tPA-mediated plasmin generation occurs. tPA cleaves the zymogen plasminogen at its Arg561 - Val562 peptide bond, into the serine protease plasmin. Increased enzymatic activity causes hyperfibrinolysis, which manifests as excessive bleeding and/or an increase of the vascular permeability. Decreased activity leads to hypofibrinolysis, which can result in thrombosis or embolism. In patients with ischemic strokes, decreased tPA activity was reported to be associated with an increase in plasma P-selectin concentration. Tissue plasminogen activator also plays a role in cell migration and tissue remodeling.
== Pharmacokinetics == Icodextrin is not significantly metabolised inside the peritoneum. Instead, it is absorbed slowly (40% after 12 hours) into the bloodstream via the lymph vessels. There it is broken down into oligosaccharides by the enzyme alpha-amylase. In patients with intact kidney function, both icodextrin and its fragments are excreted via the kidney by glomerular filtration.
== Chemistry == Lercanidipine is used in form of the hydrochloride, which is a slightly yellow crystalline powder and melts at 197 to 201 °C (387 to 394 °F) in crystal form I or 207 to 211 °C (405 to 412 °F) in crystal form II. It is readily soluble in chloroform and methanol, but practically insoluble in water. This high lipophilicity (compared to older dihydropyridines) is intentional because it causes the substance to bind to lipid membranes, allowing for a longer duration of action. The lercanidipine molecule has one asymmetric carbon atom. While the S-enantiomer is more effective than the R-enantiomer, marketed formulations contain a 1:1 mixture of both (i.e., the racemate).
=== Koded solutions === These are solutions containing FSL Kode constructs where the construct will exist as a clear micellular dispersion. FSL-GB3 as a solution/gel has been used to inhibit HIV infection and to neutralise Shiga toxin. FSL blood group A as a solution has been used to neutralise circulating antibodies in a mouse model and allow incompatible blood group A (murine kodecytes) transfusion. This model experiment was used to demonstrate the potential of FSLs to neutralise circulating antibody and allow for incompatible blood transfusion or organ transplantation.
Sources: en.wikipedia.org
Protactinium is a chemical element; it has symbol Pa and atomic number 91. It is a dense, radioactive, silvery-gray actinide metal which readily reacts with oxygen, water vapor, and inorganic acids. It forms various chemical compounds, in which protactinium is usually present in the oxidation state +5, but it can also assume +4 and even +3 or +2 states. Concentrations of protactinium in the Earth's crust are typically a few parts per trillion, but may reach up to a few parts per million in some uraninite ore deposits. Because of its scarcity, high radioactivity, and high toxicity, there are currently no uses for protactinium outside scientific research, and for this purpose, protactinium is mostly extracted from spent nuclear fuel. It is also the only highly radioactive mononuclidic element that is not also monoisotopic, occurring almost exclusively through the decay of Uranium-235. The element was first identified in 1913 by Kazimierz Fajans and Oswald Helmuth Göhring and named "brevium" because of the short half-life of the specific isotope studied, 234mPa. A more stable isotope of protactinium, 231Pa, was discovered in 1917/18 by Lise Meitner in collaboration with Otto Hahn, and they named the element protactinium. In 1949, the IUPAC chose the name "protactinium" and confirmed Hahn and Meitner as its discoverers. The new name meant "(nuclear) precursor of actinium," suggesting that actinium is a product of radioactive decay of protactinium.
=== Growth and proliferation === Intracrines such as fibroblast growth factor-2 (FGF2), vascular endothelial growth factor (VEGF), and insulin-like growth factor-1 (IGF-1) regulate cellular proliferation. In cancer, these factors often establish self-sustaining feed-forward loops, enhancing uncontrolled tumor growth. For example, VEGF's intracrine action is implicated in hematopoietic malignancies, while angiogenin has been identified in the nuclei of breast cancer cells, where it promotes proliferation.
==== Cannabinoids ==== According to a study published in the August 15, 2004 issue of the journal Cancer Research, cannabinoids, the active ingredients in marijuana, restrict the sprouting of blood vessels to gliomas (brain tumors) implanted under the skin of mice, by inhibiting the expression of genes needed for the production of vascular endothelial growth factor (VEGF).
=== Diagnosis and treatment === In current practice for dogs, B. canis is diagnosed using PCR, cultures, and serologic testing. The most standard test for B. canis is culture. These cultures are typically conducted on the host's blood, vaginal discharge, or semen. However, this method is not effective if the dog has been treated with antimicrobial drugs, as this will clear B. canis bacteria even if the disease has not resolved. Serology is used to evaluate the antibody response against Brucella spp. cell wall antigens, the downfall of this method is its lack of specificity. PCR testing has shown potential as a rapid test, however it is not readily available and is currently considered an experimental test. Currently, there are not commercially available vaccines for B. canis. Antimicrobial treatment and sterilization of the infected animals is considered an alternative to removing the animal. There have been reports of anti-Brucella vaccines (used for cattle and small ruminants), used along with previously mentioned methods but is not considered practical due to its risk of vaccine strain shedding in a domestic environment with current vaccines maintaining an amount of virulence for humans. Treatment for B. canis is very difficult to find and often very expensive. This is due to B. canis being a intracellular bacteria, meaning it replicates inside of host cells rather than outside of them. This makes it difficult for antibiotics to reach the bacteria.
Professor Mary Tara Marshall, Director, Dementia Services Development Centre at the University of Stirling. Lately Director, Age Concern Scotland. For services to Elderly People. Arthur Gordon Mason, Research Manager, Digi-Media Vision Ltd. For services to the Broadcasting Industry. Duncan Stuart Matthews, Head of Innovation and Growth Unit, National Westminster Bank plc. For services to Banking and to Industry. Kenneth McAlpine, . For services to the English Vineyard Association and to English Wine. James McIntosh McCabe, . For political service. Andrew Duncan McCracken, lately Principal Officer, Howdenhall/St. Katharine's Centre, Edinburgh. For services to Child Care. David Alexander McCubbin. For services to people with learning disabilities. Professor Damien Gerard McDonnell, Senior Principal Scientific Officer, the Defence Evaluation and Research Agency, Ministry of Defence. James Dobbie McFarlane, lately Major Projects Director, Engineering Division, Nuclear Electric plc. For services to the Nuclear Electric Industry. William McGinnis, . For services to the Sheet Metal Industry and to Industry. Roger McGough, Poet. For services to Poetry. Helen Frances McGrath, President, National Union of Knitwear, Footwear and Apparel Trades. For services to Industrial Relations. Stuart McKenzie. For services to the Sea Cadet Corps, Southern Area. Donald McNeill, lately Chief Executive, South Ayrshire Hospitals NHS Trust. For services to Health Care. Professor David Alan Redpath Michie, Artist. For services to Art Jean Monro. For services to Interior Design.
Sources: en.wikipedia.org
Lyophilized peptides are typically stored at -20 °C or lower, protected from moisture and light. Solutions are often stored at -80 °C and divided into single-use aliquots. Repeated freeze-thaw cycles should be avoided.
Oxidation of methionine and deamidation of asparagine are frequent reactions. Hydrolysis of peptide bonds can occur under acidic or basic conditions. Each pathway produces impurities that reduce purity.
Specifications depend on the intended use and supplier. Common minimums are 95% or 98% by HPLC area percentage. Identity and counterion content are also checked.
HPLC purity measures the relative area of the main peptide peak compared with all detected peaks under one set of separation and detection conditions. It is an operational value rather than an absolute mass fraction. Compounds that do not absorb at the detection wavelength or that co-elute with the main peak are not counted.